IN THIS ISSUE
Legislation & Regulation
John Carroll
The SGR, ill-conceived and continually bypassed, may be nearing the end of its pathetic, useless life
Plan Watch
Frank Diamond

The insurer studies exactly what works and why in studying two programs that battle diabetes

Tomorrow's Medicine
Thomas Morrow, MD

This population can benefit from Juxtapid and Kynamro, but the cost is not addressed by health reform